Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Bieber

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Acta Dermato-Venereologica|February 11, 2020
Drug Development in Pemphigoid DiseasesKatja Bieber, Ralf J Ludwig
Experimental Dermatology|August 24, 2017
In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseasesKatja Bieber, Hiroshi Koga, Wataru Nishie
Frontiers in Immunology|August 18, 2022
IL-10 revisited in systemic lupus erythematosusSwayanka Biswas, Katja Bieber, Rudolf Armin Manz
Frontiers in Immunology|May 28, 2019
Current Clinical Trials in Pemphigus and PemphigoidKentaro Izumi, Katja Bieber, Ralf J Ludwig
Current Protocols in Pharmacology|February 21, 2019
Drug Discovery for Pemphigoid DiseasesAnika Kasprick, Katja Bieber, Ralf J Ludwig
Current Pharmaceutical Design|March 18, 2015
Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatosesHiroaki Iwata, Katja Bieber, Misa Hirose, et al.
Journal of the American Academy of Dermatology|August 10, 2023
Risk of comorbid autoimmune diseases in patients with immunobullous disorders: A global large-scale cohort studyMichael Kasperkiewicz, Artem Vorobyev, Katja Bieber, et al.
Expert Opinion on Therapeutic Targets|February 4, 2016
Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisitaMareike Witte, Hiroshi Koga, Takashi Hashimoto, et al.
Acta Dermato-Venereologica|April 7, 2025
Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis ModelsSören Dräger, Thorge Mester, Hermann Tenor, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 26, 2025
The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort studyKhalaf Kridin, Mariam Abdelghaffar, Katja Bieber, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Acta Dermato-Venereologica|February 11, 2020
Drug Development in Pemphigoid DiseasesKatja Bieber, Ralf J Ludwig
Experimental Dermatology|August 24, 2017
In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseasesKatja Bieber, Hiroshi Koga, Wataru Nishie
Frontiers in Immunology|August 18, 2022
IL-10 revisited in systemic lupus erythematosusSwayanka Biswas, Katja Bieber, Rudolf Armin Manz
Frontiers in Immunology|May 28, 2019
Current Clinical Trials in Pemphigus and PemphigoidKentaro Izumi, Katja Bieber, Ralf J Ludwig
Current Protocols in Pharmacology|February 21, 2019
Drug Discovery for Pemphigoid DiseasesAnika Kasprick, Katja Bieber, Ralf J Ludwig
Current Pharmaceutical Design|March 18, 2015
Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatosesHiroaki Iwata, Katja Bieber, Misa Hirose, et al.
Journal of the American Academy of Dermatology|August 10, 2023
Risk of comorbid autoimmune diseases in patients with immunobullous disorders: A global large-scale cohort studyMichael Kasperkiewicz, Artem Vorobyev, Katja Bieber, et al.
Expert Opinion on Therapeutic Targets|February 4, 2016
Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisitaMareike Witte, Hiroshi Koga, Takashi Hashimoto, et al.
Acta Dermato-Venereologica|April 7, 2025
Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis ModelsSören Dräger, Thorge Mester, Hermann Tenor, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 26, 2025
The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort studyKhalaf Kridin, Mariam Abdelghaffar, Katja Bieber, et al.
Pageof 12